July 28, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation
 

Tokyo, Apr 24, 2014 (JCN) - Nitto Denko Corporation has been developing a new RNAi based drug for treating fibrosis in liver and other organs since 2008 in collaboration with Prof. Yoshiro Niitsu of Sapporo Medical University.

In June 2013, Nitto initiated a phase-1 clinical study in the US, and it is happy to announce that dosing in healthy volunteers has been completed. Currently, Nitto is advancing the drug to phase-1/2 clinical study in patients for the assessment of safety and efficacy.

Nitto's new anti-fibrotic therapy consists of siRNA which specifically inhibits the cause of fibrosis as well as a targeted lipid nanoparticle delivery system which can deliver the siRNA to the cells responsible for fibrosis. Therefore, the new drug has a dual targeting mechanism in both drug delivery and action.

Furthermore, this anti-fibrosis therapy can be a revolutionary drug which leads complete resolution of liver fibrosis and other organ fibrosis, which is not available so far.

Nitto also obtained relevant granted intellectual properties of therapeutic modality in Japan, US, Europe, China, Canada, Australia and Korea, as well as drug formulations including siRNA and DDS.

Nitto is also pursuing research activities in tissue regeneration mechanisms related to our therapeutic modality, in addition to new oncology programs which were derived from fibrosis drug development.

Those research activities are carried out with collaborations and supports from Sapporo Medical University and Hokkaido University and others.

Nitto plans to initiate phase-1/2 clinical study in US this year in order to assess safety and efficacy in patients, and expects to collaborate with pharmaceutical company from late phase-2 stage toward approval from the agency in 2018 or after.


By Chris Lui Staff Writer

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Nitto Denko Corporation News  
  Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation  (Apr 24, 2014)
  Nitto Denko Launches New Encapsulation Sheet for LED  (Feb 15, 2013)
  Nitto Denko Develops Optical Touch-screen Technology for 'Smart' Stationery  (July 12, 2011)
  Nitto Denko Group Wins RO Membrane Orders for Big Australian Seawater Desalination Plant Project  (June 25, 2010)
  Nitto Denko, Kobe University Selected for Joint Bioethanol R&D by NEDO  (Sept 11, 2009)
  Nitto Denko Invests S$10 Million To Pioneer Organic Electronic Device Research In Singapore  (Dec 1, 2008)
  Nitto Denko Invests S$10 Million To Pioneer Organic Electronic Device Research In Singapore  (Dec 1, 2008)
  Cutting-edge Nitto Denko Biomedical R&D Wins Government Support  (Dec 1, 2008)
  Nitto Denko Plans Water R&D Center in Singapore; New Center to be Development Hub for Cutting-edge Water Treatment Technologies  (June 25, 2008)
  Nitto Denko to Set Up R&D Base in Singapore  (June 23, 2008)



 Recent  Drugs & OTC News   
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)
EIZO, Stryker to Partner in Monitor Management Systems for Operating Rooms (Oct 8, 2013)
HOYA to Invest in EndoMaster, for Robotic-assisted Surgical Systems (Aug 19, 2013)
Dainippon Screen Launches High-speed Three-dimensional Cell Culture Scanner (Aug 8, 2013)
Daiichi Sankyo Expands Collaborative Drug Discovery Program to Germany, Switzerland, and Austria (Aug 1, 2013)

More Drugs & OTC news...
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)